Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Basilea Pharmaceutica

+ Add to Watchlist

BSLN:SW

121.50 CHF 0.70 0.57%

As of 12:53:40 ET on 02/27/2015.

Snapshot for Basilea Pharmaceutica (BSLN)

Open: 122.20 Day's Range: 120.90 - 123.50 Volume: 61,734
Previous Close: 122.20 52wk Range: 79.75 - 129.60 1-Yr Rtn: -6.03%

Stock Chart for BSLN

No chart data available.
  • BSLN:SW 121.40
  • 1D
  • 1M
  • 1Y
122.20
Interactive BSLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BSLN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SMI -
Earnings Per Share (CHF) (ttm) -4.0700
Est. EPS (CHF) (12/2015) -4.1950
Est. PEG Ratio -
Market Cap (M CHF) 1,239.33
Shares Outstanding (M) 10.20
30 Day Average Volume 91,129
Price/Book (mrq) 22.1797
Price/Sale (ttm) 29.0122
Dividend Indicated Gross Yield -%
Cash Dividend (CHF) 5.0000
Dividend Ex-Date 04/11/2013
5 Year Dividend Growth -
Next Earnings Announcement 08/14/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BSLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for BSLN

Basilea Pharmaceutica AG is a biotechnology company conducting research into the development of drugs for the treatment of infectious diseases and dermatological problems. The Company develops anti-bacterial and anti-fungal compounds which destroy infectious organisms.

Domenico ScalaVice ChairmanRonald Scott "Ron"Chief Executive Officer
Donato SpotaChief Financial OfficerDavid VeitchChief Commercial Officer
More Company Profile & Key Executives for BSLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil